Global Intravenous Immune Globulin Therapies 麻豆原创 Research Report 2024

Publication ID:

PB505250204

Publication Date:

May 7, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Immune globulin derived from the plasma of paid and volunteer donors is used in the treatment of an array of disorders, including primary and secondary immune deficiency states and a variety of autoimmune and inflammatory disorders.
The global Intravenous Immune Globulin Therapies market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Intravenous Immune Globulin Therapies is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Intravenous Immune Globulin Therapies is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Intravenous Immune Globulin Therapies in Immunodeficiency is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Intravenous Immune Globulin Therapies include Baxter, Grifols, CSL Plasma, Octapharma, Biotest, Kedrion, Kamada, China Biologic Products Holdings and Hualan Biological Engineering, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Intravenous Immune Globulin Therapies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Intravenous Immune Globulin Therapies.
Report Scope
The Intravenous Immune Globulin Therapies market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Intravenous Immune Globulin Therapies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Intravenous Immune Globulin Therapies companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Baxter
Grifols
CSL Plasma
Octapharma
Biotest
Kedrion
Kamada
China Biologic Products Holdings
Hualan Biological Engineering
Sichuan Yuanda Shuyang Pharmaceutical
Segment by Type
Liquid Form
Lyophilized Powder Form
Segment by Application
Immunodeficiency
Autoimmune Disease
Acute Infection
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Intravenous Immune Globulin Therapies companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Intravenous Immune Globulin Therapies 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Liquid Form
1.2.3 Lyophilized Powder Form
1.3 麻豆原创 by Application
1.3.1 Global Intravenous Immune Globulin Therapies 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Immunodeficiency
1.3.3 Autoimmune Disease
1.3.4 Acute Infection
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Intravenous Immune Globulin Therapies 麻豆原创 Perspective (2019-2030)
2.2 Intravenous Immune Globulin Therapies Growth Trends by Region
2.2.1 Global Intravenous Immune Globulin Therapies 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Intravenous Immune Globulin Therapies Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Intravenous Immune Globulin Therapies Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Intravenous Immune Globulin Therapies 麻豆原创 Dynamics
2.3.1 Intravenous Immune Globulin Therapies Industry Trends
2.3.2 Intravenous Immune Globulin Therapies 麻豆原创 Drivers
2.3.3 Intravenous Immune Globulin Therapies 麻豆原创 Challenges
2.3.4 Intravenous Immune Globulin Therapies 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Intravenous Immune Globulin Therapies Players by Revenue
3.1.1 Global Top Intravenous Immune Globulin Therapies Players by Revenue (2019-2024)
3.1.2 Global Intravenous Immune Globulin Therapies Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Intravenous Immune Globulin Therapies 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Intravenous Immune Globulin Therapies Revenue
3.4 Global Intravenous Immune Globulin Therapies 麻豆原创 Concentration Ratio
3.4.1 Global Intravenous Immune Globulin Therapies 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Intravenous Immune Globulin Therapies Revenue in 2023
3.5 Intravenous Immune Globulin Therapies Key Players Head office and Area Served
3.6 Key Players Intravenous Immune Globulin Therapies Product Solution and Service
3.7 Date of Enter into Intravenous Immune Globulin Therapies 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Intravenous Immune Globulin Therapies Breakdown Data by Type
4.1 Global Intravenous Immune Globulin Therapies Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Intravenous Immune Globulin Therapies Forecasted 麻豆原创 Size by Type (2025-2030)
5 Intravenous Immune Globulin Therapies Breakdown Data by Application
5.1 Global Intravenous Immune Globulin Therapies Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Intravenous Immune Globulin Therapies Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Intravenous Immune Globulin Therapies 麻豆原创 Size (2019-2030)
6.2 North America Intravenous Immune Globulin Therapies 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Intravenous Immune Globulin Therapies 麻豆原创 Size by Country (2019-2024)
6.4 North America Intravenous Immune Globulin Therapies 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Intravenous Immune Globulin Therapies 麻豆原创 Size (2019-2030)
7.2 Europe Intravenous Immune Globulin Therapies 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Intravenous Immune Globulin Therapies 麻豆原创 Size by Country (2019-2024)
7.4 Europe Intravenous Immune Globulin Therapies 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Intravenous Immune Globulin Therapies 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Intravenous Immune Globulin Therapies 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Intravenous Immune Globulin Therapies 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Intravenous Immune Globulin Therapies 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Intravenous Immune Globulin Therapies 麻豆原创 Size (2019-2030)
9.2 Latin America Intravenous Immune Globulin Therapies 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Intravenous Immune Globulin Therapies 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Intravenous Immune Globulin Therapies 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Intravenous Immune Globulin Therapies 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Intravenous Immune Globulin Therapies 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Intravenous Immune Globulin Therapies 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Intravenous Immune Globulin Therapies 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Baxter
11.1.1 Baxter Company Detail
11.1.2 Baxter Business Overview
11.1.3 Baxter Intravenous Immune Globulin Therapies Introduction
11.1.4 Baxter Revenue in Intravenous Immune Globulin Therapies Business (2019-2024)
11.1.5 Baxter Recent Development
11.2 Grifols
11.2.1 Grifols Company Detail
11.2.2 Grifols Business Overview
11.2.3 Grifols Intravenous Immune Globulin Therapies Introduction
11.2.4 Grifols Revenue in Intravenous Immune Globulin Therapies Business (2019-2024)
11.2.5 Grifols Recent Development
11.3 CSL Plasma
11.3.1 CSL Plasma Company Detail
11.3.2 CSL Plasma Business Overview
11.3.3 CSL Plasma Intravenous Immune Globulin Therapies Introduction
11.3.4 CSL Plasma Revenue in Intravenous Immune Globulin Therapies Business (2019-2024)
11.3.5 CSL Plasma Recent Development
11.4 Octapharma
11.4.1 Octapharma Company Detail
11.4.2 Octapharma Business Overview
11.4.3 Octapharma Intravenous Immune Globulin Therapies Introduction
11.4.4 Octapharma Revenue in Intravenous Immune Globulin Therapies Business (2019-2024)
11.4.5 Octapharma Recent Development
11.5 Biotest
11.5.1 Biotest Company Detail
11.5.2 Biotest Business Overview
11.5.3 Biotest Intravenous Immune Globulin Therapies Introduction
11.5.4 Biotest Revenue in Intravenous Immune Globulin Therapies Business (2019-2024)
11.5.5 Biotest Recent Development
11.6 Kedrion
11.6.1 Kedrion Company Detail
11.6.2 Kedrion Business Overview
11.6.3 Kedrion Intravenous Immune Globulin Therapies Introduction
11.6.4 Kedrion Revenue in Intravenous Immune Globulin Therapies Business (2019-2024)
11.6.5 Kedrion Recent Development
11.7 Kamada
11.7.1 Kamada Company Detail
11.7.2 Kamada Business Overview
11.7.3 Kamada Intravenous Immune Globulin Therapies Introduction
11.7.4 Kamada Revenue in Intravenous Immune Globulin Therapies Business (2019-2024)
11.7.5 Kamada Recent Development
11.8 China Biologic Products Holdings
11.8.1 China Biologic Products Holdings Company Detail
11.8.2 China Biologic Products Holdings Business Overview
11.8.3 China Biologic Products Holdings Intravenous Immune Globulin Therapies Introduction
11.8.4 China Biologic Products Holdings Revenue in Intravenous Immune Globulin Therapies Business (2019-2024)
11.8.5 China Biologic Products Holdings Recent Development
11.9 Hualan Biological Engineering
11.9.1 Hualan Biological Engineering Company Detail
11.9.2 Hualan Biological Engineering Business Overview
11.9.3 Hualan Biological Engineering Intravenous Immune Globulin Therapies Introduction
11.9.4 Hualan Biological Engineering Revenue in Intravenous Immune Globulin Therapies Business (2019-2024)
11.9.5 Hualan Biological Engineering Recent Development
11.10 Sichuan Yuanda Shuyang Pharmaceutical
11.10.1 Sichuan Yuanda Shuyang Pharmaceutical Company Detail
11.10.2 Sichuan Yuanda Shuyang Pharmaceutical Business Overview
11.10.3 Sichuan Yuanda Shuyang Pharmaceutical Intravenous Immune Globulin Therapies Introduction
11.10.4 Sichuan Yuanda Shuyang Pharmaceutical Revenue in Intravenous Immune Globulin Therapies Business (2019-2024)
11.10.5 Sichuan Yuanda Shuyang Pharmaceutical Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Baxter
Grifols
CSL Plasma
Octapharma
Biotest
Kedrion
Kamada
China Biologic Products Holdings
Hualan Biological Engineering
Sichuan Yuanda Shuyang Pharmaceutical

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.